Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients

Transplantation

Volumn 93, Issue 3, 2012, Pages 325-330

  Chen, Yan ^a,b   Sampaio, Marcelo S ^a   Yang, Jae Wook ^c   Min, David ^a,d   Hutchinson, Ian V ^a,b  

^a National Institute of Transplantation Los Angeles   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Haplotype; NFAT; NODAT; Tagging SNP

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENE PRODUCT; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INCIDENCE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES AFTER TRANSPLANTATION; NFATC4 GENE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; DIABETES MELLITUS; FEMALE; HAPLOTYPES; HISPANIC AMERICANS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NFATC TRANSCRIPTION FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84862829887     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823f7f26     Document Type: Article

References (22)

1. Holmkvist J, Almgren P, Lyssenko V, et al. Common variants in maturity-onset diabetes of the young genes and future risk of type 2 diabetes. Diabetes 2008; 57: 1738.
2. Ghisdal L, Baron C, Le Meur Y, et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 2009; 20: 2459.
3. Rodrigo E, Fernández-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: Risk factors. J AmSoc Nephrol 2006; 17(12 suppl 3): S291.
4. Heit JJ. Calcineurin/NFAT signaling in the beta-cell: From diabetes to new therapeutics. Bioessays 2007; 29: 1011.
5. Kim HB, Kong M, Kim TM, et al. NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. Diabetes 2006; 55: 1342.
6. Crabtree GR, Olson EN. NFAT signaling: Choreographing the social lives of cells. Cell 2002; 109(suppl): S67.
7. Aoyama T, Nagayama S, Okamoto T, et al. Mutation analyses of the NFAT1 gene in chondrosarcomas and enchondromas. Cancer Lett 2002; 186: 49.
8. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 1997; 15: 707.
9. Kiani A, Kuithan H, Kuithan F, et al. Expression analysis of nuclear factor of activated T cells (NFAT) during myeloid differentiation of CD34- cells: Regulation of Fas ligand gene expression in megakaryocytes. Exp Hematol 2007; 35: 757.
10. Kiani A, Rao A, Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000; 12: 359.
11. Hogan PG, Chen L, Nardone J, et al. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003; 17: 2205.
12. Umpierrez GE, Gonzalez A, Umpierrez D, et al. Diabetes mellitus in the Hispanic/Latino population: An increasing health care challenge in the United States. Am J Med Sci 2007; 334: 274.
13. Balla A, Chobanian M. New-onset diabetes after transplantation: A review of recent literature. Curr Opin Organ Transplant 2009; 14: 375.
14. Willer CJ, Bonnycastle LL, Conneely KN, et al. Screening of 134 single nucleotide polymorphisms (SNPs) previously associated with type 2 diabetes replicates association with 12 SNPs in nine genes. Diabetes 2007; 56: 256.
15. Yang TT, Suk HY, Yang X, et al. Role of transcription factor NFAT in glucose and insulin homeostasis. Mol Cell Biol 2006; 26: 7372.
16. Xu Z, Taylor JA. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37 (suppl 2): W600.
17. Molkentin JD, Antos CL, Markham B, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93: 215.
18. Pescovitz MD, Nezakatgoo N, Lorber MI, et al. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation. Transplantation 2009; 88: 1010.
19. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128.
20. Johnston O, Rose CL, Webster AC, et al. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
21. Teuteberg J, Hanley-Yanez K, Pippi E, et al. 558: Pharmacogenetic interaction of the NFAT C/G polymorphism and the impact of induction therapy on freedom from significant rejection after cardiac transplantation. J Heart Lung Transplant 2009; 28(2 suppl 1): S260.
22. Poirier O, Nicaud V, McDonagh T, et al. Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. Eur JHumGenet 2003; 11: 659.